Overview

Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.

Status:
Completed

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

This study will compare the efficacy and safety of a single dose of a lidocaine 8 mg + cetylpyridimium chloride (CPC) 2 mg lozenge with a single dose of a lidocaine 1 mg + CPC 2 mg lozenge in the treatment of sore throat due to a common cold.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Cetylpyridinium
Lidocaine